Cargando…

Oncolytic Adenoviruses in Cancer Treatment

The therapeutic use of viruses against cancer has been revived during the last two decades. Oncolytic viruses replicate and spread inside tumors, amplifying their cytotoxicity and simultaneously reversing the tumor immune suppression. Among different viruses, recombinant adenoviruses designed to rep...

Descripción completa

Detalles Bibliográficos
Autor principal: Alemany, Ramon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423481/
https://www.ncbi.nlm.nih.gov/pubmed/28548059
http://dx.doi.org/10.3390/biomedicines2010036
_version_ 1783234954826612736
author Alemany, Ramon
author_facet Alemany, Ramon
author_sort Alemany, Ramon
collection PubMed
description The therapeutic use of viruses against cancer has been revived during the last two decades. Oncolytic viruses replicate and spread inside tumors, amplifying their cytotoxicity and simultaneously reversing the tumor immune suppression. Among different viruses, recombinant adenoviruses designed to replicate selectively in tumor cells have been clinically tested by intratumoral or systemic administration. Limited efficacy has been associated to poor tumor targeting, intratumoral spread, and virocentric immune responses. A deeper understanding of these three barriers will be required to design more effective oncolytic adenoviruses that, alone or combined with chemotherapy or immunotherapy, may become tools for oncologists.
format Online
Article
Text
id pubmed-5423481
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54234812017-05-23 Oncolytic Adenoviruses in Cancer Treatment Alemany, Ramon Biomedicines Review The therapeutic use of viruses against cancer has been revived during the last two decades. Oncolytic viruses replicate and spread inside tumors, amplifying their cytotoxicity and simultaneously reversing the tumor immune suppression. Among different viruses, recombinant adenoviruses designed to replicate selectively in tumor cells have been clinically tested by intratumoral or systemic administration. Limited efficacy has been associated to poor tumor targeting, intratumoral spread, and virocentric immune responses. A deeper understanding of these three barriers will be required to design more effective oncolytic adenoviruses that, alone or combined with chemotherapy or immunotherapy, may become tools for oncologists. MDPI 2014-02-21 /pmc/articles/PMC5423481/ /pubmed/28548059 http://dx.doi.org/10.3390/biomedicines2010036 Text en © 2014 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Alemany, Ramon
Oncolytic Adenoviruses in Cancer Treatment
title Oncolytic Adenoviruses in Cancer Treatment
title_full Oncolytic Adenoviruses in Cancer Treatment
title_fullStr Oncolytic Adenoviruses in Cancer Treatment
title_full_unstemmed Oncolytic Adenoviruses in Cancer Treatment
title_short Oncolytic Adenoviruses in Cancer Treatment
title_sort oncolytic adenoviruses in cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423481/
https://www.ncbi.nlm.nih.gov/pubmed/28548059
http://dx.doi.org/10.3390/biomedicines2010036
work_keys_str_mv AT alemanyramon oncolyticadenovirusesincancertreatment